Literature DB >> 12090341

Update on the medical management of benign prostatic hyperplasia.

Manoj Monga1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12090341     DOI： 10.1023/a:1014405019814

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  8 in total

Review 1.  Medical management of benign prostatic hyperplasia.

Authors:  A Chacon; M Monga
Journal:  Geriatr Nephrol Urol       Date:  1999

2.  A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.

Authors:  S J Foley; L Z Soloman; A W Wedderburn; K M Kashif; D Summerton; V Basketter; S A Holmes
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

3.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

Authors:  C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

4.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

5.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

6.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

7.  Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.

Authors:  C G Roehrborn; R Bruskewitz; G C Nickel; S Glickman; C Cox; R Anderson; S Kandzari; R Herlihy; G Kornitzer; B T Brown; H L Holtgrewe; A Taylor; D Wang; J Waldstreicher
Journal:  Eur Urol       Date:  2000-05       Impact factor: 20.096

8.  Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate.

Authors:  C J Girman; S J Jacobsen; H A Guess; J E Oesterling; C G Chute; L A Panser; M M Lieber
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450
  8 in total
  1 in total

1.  Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.

Authors:  Wenqing Gao; Jeffrey D Kearbey; Vipin A Nair; Kiwon Chung; A F Parlow; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2004-08-12       Impact factor: 4.736
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.